Less Ads, More Data, More Tools Register for FREE

Pin to quick picksSpectra (di/ S) Regulatory News (SPSC)

Share Price Information for Spectra (di/ S) (SPSC)

Share Price is delayed by 15 minutes
Get Live Data
160.00    0.00 (0.00%)
Bid:
120.00
Ask:
200.00
Spread: 80.00 (66.667%)
Market Cap: £77.39m
SPSC Live PriceLast checked at - London Stock Exchange

Intraday Spectra (di/ S) Share Chart

Share Buyback Programme

25 Nov 2025 07:00

RNS Number : 8151I
Spectra Systems Corporation
25 November 2025
 

Spectra Systems Corporation

(The "Company" or "Spectra Systems")

Share Buyback Programme

Spectra Systems, a leader in machine-readable high speed banknote authentication, brand protection technologies and gaming security software, announces the launch of an initial share buyback programme of unrestricted common shares of US$0.01 each ("Common Shares") to repurchase up to US$350,000 worth of Common Shares (the "Buyback Programme"), effective from today.

The Board considers the Buyback Programme to be in the best interests of all shareholders, given the cash generative nature of the business and the surplus cash the Company holds. It is also consistent with the Board's desire to increase shareholder value/ returns.

The Company has appointed its broker, Zeus Capital Limited ("Zeus"), to manage the Buyback Programme to repurchase Ordinary Shares on its behalf and entered into an irrevocable and non-discretionary arrangement on 24 November 2025 with Zeus, to enable Zeus to conduct the Buyback Programme on a broker-managed basis. Zeus will make trading decisions in relation to the Buyback Programme independently of the Company, within certain defined parameters.

The Buyback Programme commences today and will end on the earlier of the date upon which the aggregate consideration paid for Common Shares reaches US$350,000 or 5 December 2025 (the "Buyback Period"). During the Buyback Period the Company has no power to invoke any changes to the authority and any purchases will be undertaken by Zeus, acting independently of, and uninfluenced by the Company.

Common Share repurchases will take place in open market transactions and may be made from time to time depending on market conditions, share price and trading volume. The Buyback Programme is in accordance with the Company's general authority to purchase its own shares under Delaware General Corporation Law. The price paid for Common Shares under the Buyback Programme will be no more than: a) 105 per cent. of the average trading price of the Ordinary Shares as derived from the middle market quotations for an Ordinary Share on the London Stock Exchange Daily Official List for the five trading days immediately preceding the date on which an Ordinary Share is contracted to be purchased; and b) £1.35.

Under the Buyback Programme, the repurchased shares will be cancelled.

The Buyback Programme will be conducted within the parameters of the Market Abuse Regulation 596/2014/EU and the Commission Delegated Regulation 2016/1052/EU (each as in force in the UK from time to time, including where relevant pursuant to the Market Abuse (Amendment) (EU Exit) Regulations 2019.

The Company will make further announcements in due course following any share purchases conducted through the Buyback Programme.

Following this announcement, the issued share capital of the Company remains unchanged at:

· 47,758,431 shares in the unrestricted line ISIN number US84756T1060 (AIM:SPSY); and

· 542,258 shares in the Regulation S stock line ISIN number USU8457D1091 (AIM:SPSC)

Spectra Systems has no Shares in treasury, therefore 48,300,689 may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change in their interest in, the share capital of the Company under the FCA's Disclosure and Transparency Rules.

The Company confirms that it currently has no unpublished price sensitive information.

Enquiries:

 

Spectra Systems Corporation 

Dr. Nabil Lawandy, Chief Executive Officer 

Tel: +1 (0)401 274 4700 

Zeus (Nominated Adviser and Joint Broker)

James Joyce / James Bavister (Investment Banking) 

Fraser Marshall (Corporate Broking) 

 

Allenby Capital Limited (Joint Broker) 

Nick Naylor/James Reeve (Corporate Finance) 

Amrit Nahal (Sales and Corporate Broking)

Tel: +44 (0)20 3829 5000

 

Tel: +44 (0)20 3328 5665 

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
MSCPPGBWGUPAPUC
Date   Source Headline
22nd May 20262:45 pmRNSAdditional Sensor order
16th Apr 20267:00 amRNSExercise of Options and Total Voting Rights
8th Apr 20267:00 amRNSExercise of Options and Total Voting Rights
30th Mar 20267:00 amRNSAudited results for year ended 31 December 2025
5th Feb 20267:00 amRNSExecuted Contract with HMRC for Vaping Duty Stamps
16th Jan 20267:00 amRNSSuccessful Bid for HMRC Vaping Duty Stamps Scheme
8th Dec 20257:00 amRNSTransaction in Own Shares & TVR
26th Nov 20257:01 amRNSTransaction in Own Shares & TVR
26th Nov 20257:00 amRNSMaintenance contract for new sensors
25th Nov 20257:00 amRNSShare Buyback Programme
16th Oct 20257:00 amRNSAppointment of Finance Director
29th Sep 20257:00 amRNSInterim Results for Six Months Ended 30 June 2025
9th Sep 20252:59 pmRNSNotice of Interim Results
27th Jun 20257:00 amRNSExercise of Options
24th Jun 20254:48 pmRNSAnnual General Meeting Lack of Quorum
11th Jun 20257:00 amRNSNotice of AGM
27th May 20255:33 pmRNSAppointment of Finance Director
9th Apr 20254:55 pmRNSHolding(s) in Company
7th Apr 20257:00 amRNSExercise of Options & Removal of Reg S
31st Mar 20257:00 amRNSAudited results for year ended 31 December 2024
9th Jan 20257:00 amRNSExercise of Options
18th Dec 20243:58 pmRNSExercise of Options
18th Dec 20247:00 amRNS$9.4M downpayment on sensor manufacturing contract
21st Oct 20244:00 pmRNSHolding(s) in Company
30th Sep 20247:00 amRNSInterim Results
20th Aug 20244:35 pmRNSRemoval of Reg S restrictions from common stock
30th Jul 20247:00 amRNSAnnual General Meeting Lack of Quorum
18th Jul 20244:52 pmRNSHolding(s) in Company
16th Jul 20247:00 amRNSNew $37.9 million sensor manufacturing contract
15th Jul 20247:00 amRNSChange of Nominated Adviser and Broker
28th Jun 20241:46 pmRNSReplacement: Posting of Annual Report
28th Jun 202410:14 amRNSPosting of Annual Report and Notice of AGM
3rd Jun 20247:00 amRNSIssue of Equity & Update to Dividend Timetable
27th Mar 20247:00 amRNSAudited results for 12 months ended 31 Dec 2023
11th Jan 20247:00 amRNSExercise of Options and Director/PDMR Shareholding
28th Dec 20237:00 amRNSExercise of Options
21st Dec 202312:15 pmRNSCompletion of Acquisition
15th Dec 20234:35 pmRNSExercise of Options and transfer of shares
4th Dec 20237:00 amRNSAcquisition of Cartor Holdings Limited
6th Nov 20234:43 pmRNSTR-1
12th Oct 20237:00 amRNSLargest Central Bank Consumables Order
25th Sep 20237:00 amRNSInterim Results for Six Months Ended 30 June 2023
7th Jul 20236:01 pmRNSRemoval of Regulation S restrictions from shares
26th Jun 20233:22 pmRNSAnnual General Meeting Lack of Quorum
30th May 20237:00 amRNSAppointment of Chief Financial Officer
25th Apr 20237:00 amRNSAdditional Sensor Services Contract Amendment
24th Apr 20237:00 amRNSResignation of Chief Financial Officer
19th Apr 20237:05 amRNSRemoval of Reg S restrictions from common stock
6th Apr 20237:00 amRNSExercise of Options
31st Mar 20235:14 pmRNSRemoval of Reg S restrictions from shares

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.